Bixiye
QP37-24 Update for New-to-Market Medical Drugs: atidarsagene autotemcel, crovalimab, and fidanacogene eleparvovec
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Natiijooyinka Raadinta
Soo bandhiga 2161 - 2170 ee natiijooyinka 4128
Bixiye
QP43-24 MHCP Pharmacy Benefit Exclusion for Alyglo™ and Lenmeldy™
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP42-24 Commercial Pharmacy Benefit Exclusion for Lenmeldy™
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP41-24 Commercial Pharmacy Benefit Exclusion for Select Medications
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP39-24 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective July 1, 2024
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP40-24 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective June 1, 2024
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
2024 May Bulletins
Taariikhda uu dhaqangalayo Barnaamijka: May 01, 2024
Bixiye
P34-24 Updated Reimbursement Policies, Effective July 1, 2024
Taariikhda uu dhaqangalayo Barnaamijka: May 01, 2024
Bixiye
QP105-23 Change in Facility Unbundling Reviews for Members of Other Blue Plans
Taariikhda uu dhaqangalayo Barnaamijka: Des 27, 2023